SLNNasdaqPharmaceutical PreparationsAlso trades as SLNCF
Silence Therapeutics plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$19.58+10.90 (+125.58%)
Close on Oct 19, 2026
- Market cap
- $2.77B
- P/E (TTM)
- –
- Dividend yield
- –
Silence Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Silence Therapeutics | Industry median |
|---|---|---|
| Market Cap | $925.09M | $164.85M |
| Enterprise Value | $852.99M | $87.06M |
| PS Ratio | 1504.21 | 3.60 |
| PB Ratio | 24.05 | 2.03 |
| P/TBV Ratio | 32.87 | 2.31 |
Enterprise value
| Measure | Silence Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 1386.98 | 2.43 |
Income (trailing twelve months)
| Measure | Silence Therapeutics | Industry median |
|---|---|---|
| Revenue | $615.00K | $57.94M |
| Gross Profit | $528.00K | $90.47M |
| Operating Income | -$68.31M | -$21.44M |
| Pretax Income | -$59.95M | -$14.45M |
| Net Income | -$59.95M | -$22.46M |
| EBITDA | -$68.31M | -$16.91M |
| EPS (Diluted) | -$0.43 | -$0.83 |
Margins
| Measure | Silence Therapeutics | Industry median |
|---|---|---|
| Gross Margin | 85.9% | 52.3% |
| Operating Margin | -11106.8% | -44.5% |
| Pretax Margin | -9748.1% | -13.0% |
| Profit Margin | -9748.5% | -39.2% |
| EBITDA Margin | -11106.8% | -31.3% |
| FCF Margin | -6872.5% | -8.85% |
Returns
| Measure | Silence Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -90.4% | -53.1% |
| Return on Assets (ROA) | -44.1% | -41.0% |
| Return on Capital Employed (ROCE) | -72.9% | -37.8% |
Growth
| Measure | Silence Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -97.7% | 6.01% |
| Revenue Growth (3Y CAGR) | -70.4% | 2.25% |
Balance sheet
| Measure | Silence Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $72.10M | $62.42M |
| Net Cash (Debt) | $72.10M | $15.68M |
| Net Cash Per Share | $0.51 | $0.66 |
| Equity (Book Value) | $38.47M | $48.79M |
| Book Value Per Share | $0.27 | $1.36 |
| Tangible Book Value | $28.15M | $23.06M |
| Working Capital | $81.57M | $75.77M |
Financial position
| Measure | Silence Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 7.42 | 3.30 |
| Quick Ratio | 5.67 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Silence Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$42.26M | -$12.35M |
| Capital Expenditures | -$3.00K | -$1.06M |
| Free Cash Flow | -$42.27M | -$20.28M |
| FCF Per Share | -$0.30 | -$0.42 |
Efficiency
| Measure | Silence Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.00 | 0.38 |
| Revenue Per Employee | $6.99K | $398.96K |
| Profits Per Employee | -$681.28K | -$703.34K |
| Employee Count | 88 | 74 |
Dividends and yields
| Measure | Silence Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -6.48% | -22.7% |
| FCF Yield | -4.57% | -9.07% |
| Buyback Yield | -0.00% | -0.73% |
| Shareholder Yield | -0.00% | 0.00% |
Shares
| Measure | Silence Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 141,740,000 | 58,179,650 |
| Shares Change (YoY) | 0.10% | 11.1% |
| Shares Change (QoQ) | 0.02% | 0.54% |
| Float | 73,526,300 | 49,173,100 |
| Shares Held by Insiders | 48.1% | 11.6% |
| Shares Held by Institutions | 16.6% | 59.4% |
Taxes
| Measure | Silence Therapeutics | Industry median |
|---|---|---|
| Income Tax | $2.00K | $91.50K |
Scores
| Measure | Silence Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -0.78 | -0.24 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Silence Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.